ARS Pharma's Neffy Approved in China for Allergy Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 29 2025
0mins
Source: Newsfilter
- First Community Use Drug: ARS Pharma's Neffy becomes the first epinephrine product approved for community use in China for adults and children over 30 kg, expected to launch in spring 2026, addressing a significant market gap and enhancing patient self-management capabilities.
- Significant Market Potential: With approximately 4% to 8% of China's population (50 to 100 million people) at risk for food allergies, the introduction of Neffy will provide a more accessible emergency treatment option, likely improving the quality of life for these patients.
- Commercial Partnership Advantage: The exclusive licensing agreement with Pediatrix Therapeutics positions ARS Pharma to achieve up to $80 million in sales milestones, further solidifying its market presence in the biopharmaceutical sector.
- Innovative Design Technology: Neffy's needle-free design not only enhances portability and ease of use but also maintains efficacy under high temperatures and after freezing, which is expected to improve patient experience and treatment timeliness.
Analyst Views on SPRY
Wall Street analysts forecast SPRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRY is 32.50 USD with a low forecast of 30.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.480
Low
30.00
Averages
32.50
High
35.00
Current: 10.480
Low
30.00
Averages
32.50
High
35.00
About SPRY
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
